

REVENIO

Revenio Group Corporation: Interim report

January 1 – March 31, 2026

Revenio Group Corporation: Interim report January 1 – March 31, 2026

Very strong quarter in the US and EMEA, non-recurring costs weighed on profit – announced Visionix acquisition to accelerate growth and value creation

The figures in parentheses refer to the corresponding period in the previous year unless otherwise stated.

January–March 2026

- Net sales totaled EUR 27.3 (26.1) million, up by 4.8%
- The currency-adjusted net sales increased 8.4%
- Operating profit was EUR 2.4 (6.6) million, or 8.8% of net sales, down by 63.8%
- Adjusted operating profit was EUR 5.8 (6.6) million, or 21.3% of net sales, down by 12.2%
- EBITDA was EUR 3.5 (7.7) million, or 12.8% of net sales, down by 54.9%
- Cash flow from operations totaled EUR -3.4 (4.7) million
- Earnings per share came to EUR 0.092 (0.157)
- The Annual General Meeting for April 15, 2026 was cancelled and a new AGM will be held after the review period on May 12, 2026. The Board proposes that no dividend for the financial year 2025 will be paid.

NET SALES
Q1/2026

27.3 (26.1) M€

+4.8%

ADJUSTED OPERATING
PROFIT Q1/2026

5.8 (6.6) M€

-12.2%

EBITDA
Q1/2026

3.5 (7.7) M€

-54.9%

EPS
Q1/2026

0.092 (0.157) €

CURRENCY-ADJUSTED
NET SALES Q1/2026

+8.4%

Key consolidated figures

MEUR	1-3/2026	1-3/2025	Change-%
Net sales	27.3	26.1	4.8
Gross margin	18.7	19.0	-1.3
Gross margin - %	68.4	72.6	-5.8
EBITDA	3.5	7.7	-54.9
EBITDA-%	12.8	29.6	-57.0
EBITA	2.8	7.1	-60.1
EBITA-%	10.3	27.0	-62.0
Operating profit, EBIT	2.4	6.6	-63.8
Operating profit-%, EBIT	8.8	25.4	-65.5
Adjusted operating profit, EBIT	5.8	6.6	-12.2
Adjusted operating profit - %, EBIT	21.3	25.4	-16.2
Return on investment-%, ROI	2.9	5.0	-42.0
Return on equity-%, ROE	2.1	3.8	-44.7
Earnings per share	0.092	0.157	
MEUR	31.3.2026	31.3.2025	Change, %-point
Equity ratio-%	79.1	80.2	-1.1
Gearing-%	-10.1	-9.7	-0.4


Financial guidance for 2026

Due to the transaction announced on April 13, 2026, Revenio withdraws its previous financial guidance and will provide updated financial guidance for 2026 after the completion of the transaction.


Revenio's previous financial guidance, published on February 11, 2026:

Revenio Group's exchange rate-adjusted net sales are estimated to grow 8-15 percent from the previous year and profitability, excluding non-recurring items, is estimated to remain at a good level.


Net sales, M€




Cash flow from operations, M€



Adjusted operating profit, EBIT, M€



EBITDA, M€



Comments from CEO

Jouni Toijala

The execution of our growth strategy is progressing as planned toward the conclusion of our strategy period at the end of 2026. The year 2026 started very strongly in the United States on a US dollar basis. In addition to the United States, sales were particularly strong in France, the United Kingdom, and Germany. In the APAC region, market conditions remained challenging, primarily due to unfavourable currencies. In addition, the comparison period included exceptionally large deliveries. We invoice our products in euros in all markets except the United States. Currency-adjusted net sales increased by 8.4% in the first quarter. Reported net sales increased by 4.8% to EUR 27.3 (26.1) million in the first quarter. Compared to the reference period, the strengthening of the euro by more than 11% against the U.S. dollar had a negative impact on the growth of net sales in euros. Currency-adjusted growth was at a good level, especially considering the strong 12.0% growth in the comparison period.

The price increases implemented in the United States at the beginning of the year began to be reflected in improved gross margins and profitability from February onwards.

However, gross margin percentages were adversely impacted by tariffs and product mix, particularly due to the very strong growth in fundus imaging device sales.

Sales during the review period were generated from our normal order flow, and unlike in the comparison period, there were no significant one-off orders at the beginning of the year. As previously communicated, we continue to negotiate several interesting, larger-than-usual opportunities, the timing and realization of which remain difficult to predict.

Profitability was impacted by one-off acquisition-related costs

Operating profit amounted to EUR 2.4 (6.6) million, a decrease of 63.8%. Operating profit was impacted in particular by non-recurring costs of approximately EUR 3.1 million related to the Visionix acquisition. In addition, operating profit was affected by one-off costs related to organizational changes. Adjusted for non-recurring items, operating profit was EUR 5.8 (6.6) million, representing 21.3% of revenue, a decrease of 12.2%.

Cash flow from operating activities declined to EUR -3.4 (4.7) million. The decrease was primarily driven by lower reported results driven by transaction costs, increased accounts receivable following strong sales toward the end of the review period, lower accounts payable, and somewhat higher tax payments compared to the previous year. Fewer-than-expected one-off costs related to the U.S. regulatory approval process for iCare Screening Solutions were recorded during the period.

Combining forces with Visionix – focus on implementing a nimble and lightweight operating model

On April 13, 2026, after the review period, we announced the acquisition of Visionix. The transaction represents a strategically significant milestone in our company's history, strengthening our position as a global leader in ophthalmic diagnostics while accelerating the execution of our growth strategy and value creation.

By combining Revenio's strengths in intraocular pressure measurement, fundus imaging, and screening solutions with



Visionix's diagnostic expertise, we are building a comprehensive offering covering the entire care pathway. This enables us to meet the growing demand for early detection and diagnosis of eye diseases. At the same time, we gain access to the rapidly growing OCT market (Optovue), with an estimated value of approximately USD 0.7 billion, which is becoming the standard of care in the industry. The acquisition significantly strengthens our global market position. It creates a platform for value creation through revenue growth and scalability by leveraging synergies in cross-selling, product development, and operational efficiency. A key element of the integration plan is the rollout of Revenio's nimble and lightweight operating model across the organization. The integration plan has been under preparation for several months, and we will initiate the integration of the organizations without delay following the completion of the transaction.

In addition to highly complementary product and software portfolios, our value base and corporate cultures are well aligned. Strong customer focus, high-quality standards, and a commitment to continuous innovation provide an excellent foundation for successful integration and the realization of synergies.

Following the completion of the transaction, we will focus on disciplined execution of the integration, realization of synergies, and ensuring business continuity and high customer satisfaction across all markets. Our integration efforts will be guided by clear priorities: rapid capture of commercial opportunities, development of the product portfolio, and enhancement of operational efficiency.

The planned rights issue to finance the acquisition supports maintaining a balanced capital structure post-transaction and offers existing shareholders the opportunity to participate in the company's next phase of growth. The aim of the offering is to ensure sufficient financial flexibility to execute our strategy. Our largest shareholder, William Demant Invest, and the sellers of Visionix have committed to subscribe for their pro rata share (approximately 31% in total) of the offering.

The sellers of Visionix have committed to remain significant shareholders in the combined company and to participate materially in the rights issue. Their representatives are also proposed to join the Board of Directors at the upcoming General Meeting, further strengthening long-term commitment and bringing valuable expertise to the development of the company. This commitment reflects their confidence in the growth prospects of the combined company and its ability to create shareholder value.

We will host a Capital Markets Day (CMD) in autumn 2026, where we will provide an update on the integration progress and our ongoing strategy update, and outline our direction for the next strategy period 2027–2030.

Faster-than-market growth and a clear path to strong profitability

We are targeting an annual growth rate corresponding to 3x the market growth rate as well as an EBITDA margin of 25% during years 2028–2029, and an EBITDA margin approaching 30% beyond 2030.

Focus on accelerating growth and value creation

Our long-term ability to combine growth and profitability has been a key driver of Revenio's success, and we will continue to build on this foundation in the years ahead. The Visionix acquisition significantly expands our scale of operations and increases our addressable market approximately 2.5-fold, strengthening our position as a globally relevant player in ophthalmic diagnostics. With our expanded product and technology portfolio, we are better positioned to address customer needs more comprehensively and to develop new data- and AI-driven solutions that improve quality and effectiveness of care.

Our operating environment continues to be characterized by multi-layered geopolitical uncertainty, affecting, among other things, international trade and currency markets. In these conditions, our proven flexibility and ability to adapt remain our key strengths.

I would like to thank our customers, partners, employees, and shareholders for their trust and commitment to Revenio. Our focus is now on the successful completion of the Visionix acquisition and careful preparation for integration to ensure a smooth combination and effective realization of synergies. I am confident that by combining our expertise and strengths, we are building a solid foundation for profitable growth and long-term shareholder value creation.

Revenio Group's strategy

The cornerstones of the strategy for 2024–2026 are:

- Improve the quality of clinical diagnostics with targeted product innovations
- Optimize clinical care pathways with connected and predictive solutions
- Enhance customer focus in operations & sales
- Continue to develop People & Culture as a foundational strength
- Continue sustainable and profitable growth

Revenio's key products

Revenio's growth strategy is driven by delivering the highest-quality products and solutions on the market under the iCare brand. The diagnosis and treatment of eye diseases is shifting towards comprehensive patient-oriented and predictive solutions. Revenio is a pioneer in utilizing next-generation technology and artificial intelligence and improving the efficiency of care pathways. In 2025, the company invested 10.5% of net sales in research and development.

Intraocular pressure (IOP) measurement devices, i.e. tonometers

- Tonometers are innovative and easy-to-use devices for measuring intraocular pressure without numbing or air puff, making the measurement accurate and more comfortable for the patient. Tonometers are used for glaucoma screening and monitoring, and they are suitable for clinical, home and veterinary use.

Fundus imaging devices

- Fundus imaging devices provide accurate high-quality images of ocular structures, such as the retina and optic nerve end, and are used to diagnose and monitor fundus diseases, such as glaucoma, age-related macular degeneration, and diabetic retinopathy. The highly automated user-friendly devices utilize advanced technology to produce clear images without pupil dilation.

Fundus perimeters

- Fundus perimeters combine visual field examination, and exceptionally precise fundus imaging in one device for improved diagnostics accuracy. A single examination can determine both the structure and functionality of the fundus. These industry-leading devices are particularly used in the diagnosis and monitoring of glaucoma, as they allow the detection of visual field deficiencies and the evaluation of the effects of treatment.

Microperimeters

- A microperimeter combines retinal imaging and automatic visual field examination in one device, enabling simultaneous viewing of focused retinal sensitivity and monitoring of structural changes. Microperimeters are particularly used for the diagnosis and monitoring of macular degenerative diseases.

Screening solutions

- The iCare ILLUME-based screening solution combines TrueColor confocal fundus imaging with AI-powered analytics. This fully automated screening solution produces a reliable report on the patient's eye health by utilizing high-quality, detailed fundus images. Company's innovative fundus camera enables high-quality imaging without the need for uncomfortable eye drops for the patient, making the screening process fast and patient-friendly. iCare ILLUME uses artificial intelligence to help detect early signs of diabetic retinopathy, age-related macular degeneration, and glaucoma. In addition, the ILLUME Connect product allows sharing referrals between healthcare professionals. The AI-powered iCare RETCAD software is offered as a part of iCare Screening Solution and also as an individual product.

Software solutions

- The comprehensive software solutions support eye health monitoring and diagnostics by providing tools for patient data management, imaging data analysis, and long-term change tracking. They enable the integration and visualization of data collected from various devices, helping eye health professionals make accurate and up-to-date treatment decisions while streamlining care pathways.

Interim report January 1–March 31, 2026, tables

Accounting policies applied in the preparation of the interim report

This interim report is not prepared in accordance with IAS 34. Revenio Group adheres to half-year reporting in accordance with the Securities Markets Act and, for the first three and nine months of the year, publishes interim reports to present key information on the Group's financial performance. The financial figures presented in this interim report are unaudited. The financial statement bulletin and the half-year report are drawn up in accordance with IAS 34 Interim Financial Reporting.

This report has been drawn up in accordance with the same reporting principles as the 2025 financial statements, except for the following amendments to the existing standards, which the Group has applied as of January 1, 2026:

IFRS 9 and IFRS 7 amendments, as well as Annual Improvements to IFRS Accounting Standards, Part 11.

In the management's estimate, the adoption of the above-mentioned standards does not have a material impact on the Group's financial statements.

Consolidated comprehensive income statement

MEUR	1-3/2026	1-3/2025	1-12/2025
NET SALES	27.3	26.1	109.7
Other operating income	0.0	0.0	0.2
Materials and services	-8.6	-7.1	-31.9
Employee benefits	-7.0	-6.7	-26.4
Depreciation, amortization, and impairment	-1.1	-1.1	-4.5
Other operating expenses	-8.3	-4.6	-21.7
NET PROFIT/LOSS	2.4	6.6	25.4
Financial income and expenses (net)	0.9	-1.1	-2.6
PROFIT BEFORE TAXES	3.3	5.6	22.8
Income taxes	-0.8	-1.4	-5.4
NET PROFIT	2.5	4.2	17.4
Other comprehensive income items	0.0	0.0	-0.2
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	2.5	4.2	17.3
Earnings per share, EUR	0.092	0.157	0.655

Consolidated balance sheet

MEUR	31.3.2026	31.3.2025	31.12.2025
ASSETS			
NON-CURRENT ASSETS			
Goodwill	63.4	63.1	62.9
Intangible assets	23.6	22.1	23.3
Tangible assets	2.2	2.2	2.1
Right-of-use assets	4.7	2.2	5.0
Other non-current financial assets	0.5	0.4	0.5
Other receivables	0.0	0.0	0.3
Deferred tax assets	3.4	3.1	3.7
TOTAL NON-CURRENT ASSETS	97.7	93.2	97.8
CURRENT ASSETS			
Inventories	11.3	9.6	10.8
Trade and other receivables	17.8	14.7	15.8
Cash and cash equivalents	21.4	22.2	26.2
TOTAL CURRENT ASSETS	50.5	46.5	52.8
TOTAL ASSETS	148.2	139.7	150.6
SHAREHOLDERS' EQUITY AND LIABILITIES			
SHAREHOLDERS' EQUITY			
Share capital	5.3	5.3	5.3
Fair value reserve	-0.4	-0.4	-0.4
Reserve for invested unrestricted capital	52.0	52.1	52.0
Other reserves	0.3	0.3	0.3
Retained earnings/loss	61.9	56.5	59.4
Translation difference	-0.3	-0.1	-0.3
Own shares held by the company	-1.5	-1.7	-1.6
TOTAL SHAREHOLDERS' EQUITY	117.3	112.0	114.7
LIABILITIES			
NON-CURRENT LIABILITIES			
Deferred tax liabilities	3.5	3.5	3.5
Financial liabilities	1.8	6.1	3.0
Lease liabilities	3.3	1.2	3.6
TOTAL LONG-TERM LIABILITIES	8.6	10.8	10.2
CURRENT LIABILITIES			
Trade and other payables	15.8	10.9	19.3
Provisions	0.8	0.6	0.8
Financial liabilities	4.2	4.2	4.2
Lease liabilities	1.5	1.2	1.5
TOTAL CURRENT LIABILITIES	22.3	16.9	25.8
TOTAL LIABILITIES	30.9	27.7	35.9
TOTAL SHAREHOLDERS' EQUITY AND TOTAL LIABILITIES	148.2	139.7	150.6

Consolidated statement of changes in equity

MEUR	Share capital	Reserve for invested unrestricted equity	Other reserves	Retained earnings	Translation difference	Own shares	Total equity
Balance 1 Jan 2026	5.3	52.0	-0.1	59.4	-0.3	-1.6	114.7
Dividend distribution	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Disposal and purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other direct entries to retained earnings	0.0	0.0	0.0	0.1	0.0	0.0	0.1
Result for the financial period	0.0	0.0	0.0	2.5	0.0	0.0	2.5
Other comprehensive income	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Balance 31 March 2026	5.3	52.0	-0.1	61.9	-0.3	-1.5	117.3

MEUR	Share capital	Reserve for invested unrestricted equity	Other reserves	Retained earnings	Translation difference	Own shares	Total equity
Balance 1 Jan 2025	5.3	52.1	-0.1	52.2	-0.1	-1.7	107.7
Dividend distribution	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Disposal and purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other direct entries to retained earnings	0.0	0.0	0.0	0.1	0.0	0.0	0.1
Result for the financial period	0.0	0.0	0.0	4.2	0.0	0.0	4.2
Other comprehensive income	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Balance 31 March 2025	5.3	52.1	-0.1	56.5	-0.1	-1.7	112.0

Consolidated cash flow statement

MEUR	1-3/2026	1-3/2025	1-12/2025
CASH FLOW FROM OPERATIONS			
Profit for the period	2.5	4.2	17.4
Adjustments:			
Depreciation, amortization, and impairment	1.1	1.1	4.5
Other non-cash items	-0.4	0.4	1.3
Interest and other financial expenses	0.2	1.1	3.1
Interest income and other financial income	-1.0	-0.1	-0.6
Taxes	0.8	1.4	5.4
Other adjustments	0.0	0.0	-0.1
Change in working capital:			
Changes in sales and other receivables	-1.3	1.8	1.3
Changes in current assets	-0.5	0.5	-0.7
Changes in trade and other payables	-2.7	-4.4	3.5
Change in working capital, total	-4.5	-2.0	4.1
Interest paid	-0.1	-0.1	-0.4
Interest received	0.0	0.0	0.1
Taxes paid	-2.0	-1.2	-4.6
NET CASH FLOW FROM OPERATING ACTIVITIES	-3.4	4.7	30.2
CASH FLOW FROM INVESTING ACTIVITIES			
Purchase of tangible assets	-0.3	-0.1	-1.1
Purchase of intangible assets	-0.7	-0.6	-3.1
Investments in other investments	0.0	0.0	-1.1
NET CASH FLOW FROM INVESTING ACTIVITIES	-1.0	-0.7	-5.2
CASH FLOW FROM FINANCING ACTIVITIES			
Repayments of loans	-1.1	-1.1	-4.2
Dividends paid	0.0	0.0	-10.6
Payments of lease agreement liabilities	-0.4	-0.3	-1.7
NET CASH FLOW FROM FINANCING ACTIVITIES	-1.4	-1.4	-16.6
Net change in cash and credit accounts	-5.8	2.6	8.4
Cash and cash equivalents at beginning of period	26.2	20.7	20.7
Effect of exchange rates	1.0	-1.1	-2.9
Cash and cash equivalents at end of period	21.4	22.2	26.2

Key figures

MEUR	1-3/2026	1-3/2025	1-12/2025
Net sales	27.3	26.1	109.7
EBITDA	3.5	7.7	29.9
EBITDA-%	12.8	29.6	27.3
Operating profit	2.4	6.6	25.4
Operating profit-%	8.8	25.4	23.2
Pre-tax profit	3.3	5.6	22.8
Pre-tax profit-%	11.9	21.3	20.8
Net profit	2.5	4.2	17.4
Net profit-%	9.0	16.0	15.9
Gross capital expenditure	0.7	0.5	4.3
Gross capital expenditure-%	2.6	2.1	3.9
R&D costs	3.1	2.6	11.6
R&D costs-% from net sales	11.3	10.1	10.5
Gearing-%	-10.1	-9.7	-13.3
Equity ratio-%	79.1	80.2	76.1
Return on investment-% (ROI)	2.9	5.0	20.8
Return on equity-% (ROE)	2.1	3.8	15.7
Earnings per share, EUR	0.092	0.157	0.655
Equity per share, EUR	4.40	4.20	4.30
Average no. of employees	246	246	248
Cash flow from operating activities	-3.4	4.7	30.2
Cash flow from investing activities	-1.0	-0.7	-5.2
Net cash used in financing activities	-1.4	-1.4	-16.6
Total cash flow	-5.8	2.6	8.4

Alternative key figures used in financial reporting

Revenio Group Corporation has adopted the guidelines of the European Securities and Market Authority (ESMA) on Alternative Performance Measures. In addition to the IFRS-based key figures, the Company will publish certain other generally used key figures that may, as a rule, be derived from the income statement and balance sheet. The calculation of these figures is presented below. According to the Company's view, these key figures supplement the income statement and balance sheet, providing a better picture of the company's financial performance and position.

Revenio Group's reported net sales are strongly affected by fluctuations in the exchange rate between the euro and the USdollar. As an alternative key figure, the Company also presents net sales with the exchange rate effect eliminated.

Formulas

KEY FIGURE	PURPOSE	DEFINITION
EBITDA	Describes the company's operating performance before depreciation and financial items.	Operating profit + Depreciation and amortization
Gross capital expenditure	Indicates the amount of investments made in assets that generate future cash flows.	Investments in tangible and intangible assets + investments in other non-current assets + change in fair value of non-current assets + change in non-current receivables
R&D costs	Describes investments in the development of future products and technologies.	Development expenses recognized as costs + capitalized development expenses
Return on investment (ROI)	Measures the return on invested capital	$(\text{Pre-tax profit} + \text{Finance costs}) / \text{Invested capital (average)}$
Return on equity (ROE)	Measures the return on capital invested by shareholders.	$\text{Profit for the financial year} / \text{Equity (average)}$
Equity ratio	Assesses solvency by measuring the proportion of equity relative to total assets.	$\text{Equity} / \text{Total assets}$
Net leveraging (gearing)	Describes the debt burden relative to equity, taking cash assets into account.	$(\text{Interest-bearing liabilities} - \text{Cash and cash equivalents}) / \text{Equity}$
Equity attributable to equity owners of the parent company per share	Describes the amount of equity per share.	$\text{Equity} / \text{Number of shares}$
Growth in net sales, adjusted by the effect of exchange rates	Describes organic revenue growth excluding the effects of exchange rate changes.	$(\text{Net sales excluding exchange rate effects} - \text{Net sales in the comparison period}) / \text{Net sales in the comparison period}$
Adjusted operating profit (EBIT)	Presents operating profit excluding one-off items.	Operating profit + non-recurring items
Earnings before interest, taxes and amortization, EBITA	Describes the company's operating performance before amortization and financial items.	Operating profit + Amortization

1,000 EUR, unless otherwise specified

EBITDA	1–3/2026	1–3/2025
Operating profit	2,395	6,620
Depreciation and amortization	1,091	1,111
EBITDA	3,487	7,731

GROSS CAPITAL EXPENDITURE	1–3/2026	1–3/2025
Investments in tangible assets	272	143
Investments in intangible assets	694	562
Investments in other non-current assets	0	0
Change in fair value of non-current assets	0	0
Change in non-current receivables	-252	-168
Gross capital expenditure	714	537

R&D COSTS	1–3/2026	1–3/2025
Development expenses recognized as other operating expense	575	538
Development expenses recognized as employee benefit expense	1,920	1,577
Capitalized development expenses	606	519
R&D costs	3,101	2,634

RETURN ON INVESTMENT (ROI)	1–3/2026	1–3/2025
Invested capital (equity + interest-bearing liabilities) average	127,084	122,555
Pre-tax profit	3,253	5,566
Finance costs	436	600
Return on investment (ROI)	2.9%	5.0%

RETURN ON EQUITY (ROE)	1–3/2026	1–3/2025
Profit for the period	2,453	4,181
Equity (average)	114,639	109,857
Return on equity (ROE)	2.1%	3.8%

EQUITY RATIO	1–3/2026	1–3/2025
Equity	117,272	112,007
Total assets	148,182	139,667
Equity ratio	79.1%	80.2%

NET LEVERAGING (GEARING)	1–3/2026	1–3/2025
Interest-bearing liabilities	9,632	11,325
Cash and cash equivalents	21,435	22,201
Equity	117,272	112,007
Net leveraging (gearing)	-10.1%	-9.7%

EQUITY ATTRIBUTABLE TO EQUITY OWNERS OF THE PARENT COMPANY PER SHARE	1–3/2026	1–3/2025
Equity	117,272	112,007
Number of shares (1.000 pcs)	26,681	26,681
Equity attributable to equity owners of the parent company per share	4.40	4.20

GROWTH IN NET SALES, ADJUSTED BY THE EFFECT OF EXCHANGE RATES	1–3/2026	1–3/2025
Reported net sales	27,340	26,094
Effect of exchange rates on net sales	1,081	-185
Net sales adjusted by the effect of exchange rates	28,421	25,909
Growth in net sales, adjusted by the effect of exchange rates	8.4%	12.0%
Reported net sales growth	4.8%	10.5%
Difference, % points	3.6%	1.5%

ADJUSTED OPERATING PROFIT	1–3/2026	1–3/2025
Operating profit, EBIT	2,395	6,620
Costs from one-time projects	3,415	0
Adjusted operating profit, EBIT	5,810	6,620

EARNINGS BEFORE INTEREST, TAXES AND AMORTIZATION	1–3/2026	1–3/2025
Operating profit	2,395	6,620
Amortization of intangible assets	415	431
Earnings before interest, taxes and amortization, EBITA	2,810	7,051
Earnings before interest, taxes and amortization, EBITA %	10.3%	27.0%

Events after the review period

After the review period, as announced on April 13, 2026, Revenio Group Corporation (“Revenio”) and the owners of the French company LT International SAS, the parent company of the Visionix International group (“Visionix”), signed an agreement under which Revenio will acquire the entire share capital of the group parent company.

Joining forces with Visionix represents a significant milestone in the execution of Revenio’s growth strategy. It is driven by a shared ambition: to create the most innovative, creative and comprehensive entity serving eye care professionals across optometry, optical retail and ophthalmology. While the legal structure of the transaction is an acquisition, the strategic intent is to bring together two highly complementary businesses, enabling accelerated growth and value creation with greater scale and synergies. The combination will be managed as a partnership of strengths, along with leadership, capabilities and know-how from both companies helping shape the next chapter of the combined group.

Financial reporting in 2026

The half-year report H1/2026 will be published on Thursday, August 6, 2026, and the interim report Q3/2026 will be published on Thursday, October 29, 2026. The closing of the Visionix transaction will potentially have an impact on the group's reporting dates for the coming releases.

Audiocast and teleconference

Revenio will hold a live audiocast and teleconference call for analysts, investors, and media in English at 3.00 p.m. (EEST) on April 28, 2026. CEO Jouni Toijala and CFO Robin Pulkkinen will present the Interim report.

The webcast can be watched live at: <https://revenio.events.inderes.com/q1-2026>

To ask questions, please join the teleconference by registering using the following link:

<https://events.inderes.com/revenio/q1-2026/dial-in>

Phone numbers and the conference ID to access the conference will be provided after registration. To ask a question, please press #5 on your telephone keypad to enter the queue.

A recording of the webcast will be published on www.reveniogroup.fi/en after the event.

Disclaimer

This report contains certain statements that are estimates based on the management's best knowledge at the time they were made. For this reason, they involve a certain amount of inherent risk and uncertainty. The estimates may change in the event of significant changes in the general economic conditions.

Revenio Group Corporation
Board of Directors

For further information, please contact

President and CEO Jouni Toijala: +358 50 484 0085

jouni.toijala@revenio.fi

CFO Robin Pulkkinen, tel. +358 50 505 9932

robin.pulkkinen@revenio.fi

Distribution

Nasdaq Helsinki Oy

Financial Supervisory Authority (FIN-FSA)

Principal media

www.reveniogroup.fi/en

Revenio Group in brief

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio's ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, microperimeters, and perimeters as well as software solutions under the iCare brand.

In 2025, the Group's net sales totaled EUR 109.7 million, with an operating profit of EUR 25.4 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.